Front of the Eye (Anterior Segment)

Eliot Lazar, M.D.

Eliot Lazar, M.D.

Eliot Lazar, M.D., is a clinical ophthalmologist who serves as the President of elCON Medical Consulting and the Principal of elCON Medical in Buffalo, New York. Dr. Lazar has extensive experience in the commercial side of ophthalmology and other specialties. He has worked broadly in the development of devices, therapeutics, and diagnostics, and has participated in many of the critical drug delivery advances in ophthalmology and other specialties. Dr. Lazar has also collaborated with financial institutions of all sizes and scopes on both due diligence as well as at the board of directors level. Dr. Lazar has worked collaboratively with both local and global organizations on endeavors from the pre-clinical stage through the commercial stage. Dr. Lazar holds a B.S. from the University of Pennsylvania, an M.S. in Immunology from the Royal College of Surgeons, Trinity College, and the State University of New York, and an M.D. from Georgetown University School of Medicine.

Jay Pepose, M.D., Ph.D.

Jay Pepose, M.D., Ph.D.

Dr. Jay Pepose is a recognized thought leader in the field of ophthalmology, with nearly 40 years of experience as both a treating physician and a widely published researcher. He is the founder and the current Medical Director of the Pepose Vision Institute, and also founded the Midwest Corneal Research Foundation, now the Midwest Vision Research Foundation, as an independent spinout of the Pepose Vision Institute. He is a professor of clinical ophthalmology and visual sciences at Washington University School of Medicine in St. Louis, where he is a specialist in refractive surgery and corneal and external diseases. Dr. Pepose is also a consultant to the Centers for Disease Control and Prevention.

Dr. Pepose is actively involved in clinical research trials and has been the recipient of R-01 grant support from the National Eye Institute. He has served on the editorial boards of several prestigious journals, including the American Journal of Ophthalmology, Investigative Ophthalmology & Visual Science (IOVS), Cornea, and The Journal of Refractive Surgery. He has published over 210 peer-reviewed articles and a book on ocular infections and inflammatory diseases. Since 1990, Dr. Pepose has also served as an investigator on over 30 separate clinical trials, evaluating new therapeutics and technology across a broad range of ophthalmic indications, including adenoviral and bacterial conjunctivitis, meibomian gland dysfunction, dry eye disease, open-angle glaucoma, ocular hypertension, anterior uveitis, and reversal of presbyopia.

Dr. Pepose received an A.B. and M.A. in neurophysiology from Brandeis University and completed the M.D.-Ph.D. program at the UCLA School of Medicine. He completed his ophthalmology residency at the Wilmer Institute at the Johns Hopkins Medical Center and his fellowship training at Georgetown University Medical Center.

Marguerite McDonald, M.D., F.A.C.S.

Marguerite McDonald, M.D., F.A.C.S.

Marguerite McDonald, M.D., F.A.C.S., is a board-certified ophthalmologist. She received her medical degree from Columbia University College of Physicians and Surgeons and completed her internship at Lenox Hill Hospital, ophthalmology residency at Manhattan Eye Ear and Throat Hospital/Cornell, and a fellowship in corneal and external diseases at the LSU Eye Center. From 1993 to 2005, Dr. McDonald served as the director of the Southern Vision Institute in New Orleans. She is a clinical professor of ophthalmology at the NYU School of Medicine and an clinical professor of ophthalmology at Tulane University Health Sciences Center. Dr. McDonald was a professor of ophthalmology and the director of the Corneal Service at the LSU Eye Center, LSU Medical Center School of Medicine. She performed the world’s first excimer laser treatment to eliminate or reduce the need for glasses and contact lenses as well as the world’s first excimer laser surgeries for farsightedness. She was also the first North American surgeon to perform Epi-LASIK. Dr. McDonald also performed the first EBK procedure (epi-Bowman’s keratectomy) in the Americas. Dr. McDonald has over 1,800 publications, has received many awards, and has served on the editorial boards of several publications, including the Journal of Cataract and Refractive Surgery and the Journal of Refractive Surgery. She was elected the first female president of the American Society of Cataract and Refractive Surgery (ASCRS) for the 2002-03 term. In 2009-10, Dr. McDonald served as the first female president of the International Society of Refractive Surgery of the American Academy of Ophthalmology (ISRS/AAO).

Edward Holland, M.D.

Edward Holland, M.D.

Edward Holland, M.D., is the Director of Cornea Services at Cincinnati Eye Institute and a professor of ophthalmology at the University of Cincinnati. Dr. Holland is internationally known for his knowledge and expertise in the field of cornea and external diseases. Dr. Holland is the author of over 270 articles in peer-reviewed journals and has co-edited four editions of Cornea, the most widely read textbook on corneal disease and surgery. He attended the Loyola-Medical School in Chicago and trained in Ophthalmology at the University of Minnesota. He completed a fellowship in cornea and external disease at the University of Iowa, and then a second fellowship in ocular immunology at the National Eye Institute. Dr. Holland was a former member of the Board of Trustees for the American Academy of Ophthalmology and received both the Senior Achievement Award and Life Achievement Honor Award from the AAO. He also served as the President of American Society of Cataract and Refractive Surgery and presently serves as the Program Chair.

Thomas W. Samuelson, M.D.

Thomas W. Samuelson, M.D.

Thomas W. Samuelson, M.D., is a board-certified ophthalmologist who specializes in the treatment of glaucoma, cataract, and refractive surgery, as well as a founding partner and attending surgeon of Minnesota Eye Consultants. Dr. Samuelson completed his medical degree at the University of Minnesota, his residency training at the University of South Florida where he served as chief resident, and his sub-specialty training at the Wills Eye Hospital in Philadelphia. Dr. Samuelson is an adjunct professor of ophthalmology at the University of Minnesota and past chairman of the medical staff at the Phillips Eye Institute in Minneapolis. Dr. Samuelson was previously president of the American Society of Cataract and Refractive Surgery. He is the recipient of the American Academy of Ophthalmology’s Junior and Senior Achievement Awards honoring contributions made to the Academy’s educational programs. In 2018, Dr. Samuelson was awarded the AAO Lifetime Achievement Award. He also received the “Secretariate Award” for contributions to the AAO annual meeting. Dr. Samuelson has served as an examiner for the American Board of Ophthalmology and has been named as one of America’s Top Doctors each year since 2002. Dr. Samuelson served on the executive committee of the American Glaucoma Society for nearly a decade. As a member of the Basic Clinical Science Course Committee for the AAO, Dr. Samuelson helped to write the textbooks most studied by residents within the field of ophthalmology. Dr. Samuelson is the glaucoma section editor for Ocular Surgery News and serves as editorial board member and scientific reviewer for several other ophthalmology journals.

Y. Ralph Chu, M.D.

Y. Ralph Chu, M.D.

Y. Ralph Chu, M.D. is the CEO and Chief Medical Officer of the Chu Vision Institute and Chu Surgery Center in Minnesota. Dr. Chu earned his medical degree from Northwestern University in Chicago where he was a member of the Alpha Omega Alpha Honor Society. He completed his internship at Evanston Hospital, followed by a residency in ophthalmology at Duke University Eye Center. He furthered his medical training with a one-year fellowship in Minneapolis where he specialized in cornea and external disease, refractive, glaucoma, cataract, and lens implant surgery.

Dr. Chu is an internationally recognized leader, innovator, and pioneer of new technologies in cataract and refractive surgery and has been involved in over 95 clinical trials across various ophthalmic diseases. He has published over 100 national meeting presentations, abstracts, and scientific papers. Dr. Chu has also been a member of several product launch committees for refractive surgery products. Dr. Chu is a clinical investigator in Ocuphire's MIRA-3 Phase 3 clinical trial evaluating the safety and efficacy of Nyxol for reversal of mydriasis.

Jack Holladay, M.D., MSEE, F.A.C.S.

Jack Holladay, M.D., MSEE, F.A.C.S.

Jack T. Holladay, M.D., M.S.E.E., F.A.C.S., is a board-certified ophthalmologist and a clinical professor of ophthalmology at Baylor College of Medicine. Dr. Holladay has authored three books and hundreds of chapters and articles in peer-reviewed scientific journals. He serves on several editorials, medical, and scientific advisory boards, and holds numerous patents. Dr. Holladay was inducted into the Hall of Fame of the American Society of Cataract and Refractive Surgery in 2012. He is currently the Chair of the FDA/American Academy of Ophthalmology Task Force charged with developing guidelines for accommodating and extended depth of focus (EDOF) intraocular lenses (IOLs). Dr. Holladay received his medical degree and the Distinguished Alumnus Award from the University of Texas and his bachelor’s and master’s degrees in Electrical Engineering from Southern Methodist University.

James A. Katz, M.D.

James A. Katz, M.D.

James A. Katz, M.D. is a board-certified ophthalmologist and president of the Midwest Center for Sight. He is a graduate of the University of Illinois Chicago, College of Medicine. He completed his internship at Illinois Masonic Medical Center with his residency at the University of Illinois Eye & Ear Infirmary. He completed a prestigious fellowship at Casebeer International Eye Center and the University of Utah Moran Eye Center.

Dr. Katz specializes in cornea, cataract, and refractive surgery and is well-published in distinguished ophthalmologic journals with over 50 publications and over 300 presentations. He is an editorial board member of ophthalmology publications, including Cataract & Refractive Surgery Today and Presbyopia Physician. Dr. Katz has been a principal investigator in numerous FDA trials including several studies for the treatment of presbyopia. Dr. Katz speaks and teaches nationally and internationally on cataract, presbyopia and refractive surgery, and has received several notable awards and distinctions including the American Academy of Ophthalmology Achievement Award and the CEDARS ASPENS Founders Award.

Mitchell A. Jackson, M.D.

Mitchell A. Jackson, M.D.

Mitchell A. Jackson, M.D. is the founder and CEO of Jacksoneye in Illinois and has practiced as a comprehensive ophthalmologist for 28 years. He graduated from Pomona College, completed his medical training at FUHS/The Chicago Medical School, and completed his Ophthalmology residency at the University of Chicago Hospitals. Dr. Jackson has been involved in over 40 pharmaceutical and surgical device clinical studies, including several presbyopia studies. Dr. Jackson serves on 7 editorial advisory boards, including Presbyopia Physician. Dr. Jackson serves as a member of the medical advisory board of several companies, and a speaker for some of the largest ophthalmic companies. Dr. Jackson has been voted Best Cataract Surgeon in America 2021 as well as a Top 50 global Key Opinion Leaders (KOL). He is a clinical investigator in Ocuphire's MIRA-3 Phase 3 clinical trial.

Paul Karpecki, O.D., FAAO

Paul Karpecki, O.D., FAAO

Dr. Karpecki received his doctor of optometry degree from Indiana University and completed a fellowship in Cornea in Kansas City in affiliation with the Pennsylvania College of Optometry.  He currently serves as Director of Cornea Services for Kentucky Eye Institute in Lexington KY, Gaddie Eye Centers in Louisville KY, Midwest Center for Sight in Carmel IN.  He is the Chief Medical Editor for Review of Optometry, chairman of the NTT Conferences and heads the journal’s clinical content.  He is Medical Director for KEPLR Vision and for the Dry Eye Institutes of Kentucky and Indiana.  He was appointed co-chair for the previous two Tear Film and Ocular Surface Society Symposia and served on the DEWS II Diagnostic Methodology Committee.  In 2017-2018 he completed a full year preceptorship in advanced retinal disease at Retina Associates of Kentucky, one of the top 20 retina programs in the country. He currently serves as an Associate Professor at the Kentucky College of Optometry and on the board for the charitable organization Optometry Giving Sight.

Doug Devries, O.D.

Doug Devries, O.D.

Douglas Devries, O.D. is the co-founder of Eye Care Associates of Nevada and Associate Clinical Professor of Optometry. He is the director of the optometric residency program and is an Associate Clinical Professor of Optometry. Dr Devries graduated with a degree in financial management from the University of Nevada and received his Doctor of Optometry degree from Pacific University. Dr. Devries has participated in numerous clinical trials and has published over 500 national and international meeting presentations, lectures, abstracts, and scientific papers. He is an advisor and speaker for some of the largest ophthalmic pharmaceutical and device companies. He is a clinical investigator in Ocuphire's MIRA-3 Phase 3 clinical trial.

Back of the Eye (Retina)

Peter K. Kaiser, M.D.

Peter K. Kaiser, M.D.

Peter K. Kaiser, M.D., is a clinical research expert, serving as Study Chairman of 5 major, multi-center, international clinical trials, and principal investigator in numerous studies for AMD, DR, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR), Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of Retina, Retina Today, and Ocular Surgery News. He is a National Institute of Health (NIH) funded investigator, leading a team involved in the evaluation of vascular biology in age-related macular degeneration and diabetic retinopathy. Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored 7 textbooks, and more than 250 peer-reviewed papers, and has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Senior Achievement Awards and is listed as one of the “Best Doctors in America.” Dr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and Harvard Medical School. He completed an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute, Cleveland, Ohio.    

David Boyer, M.D.

David Boyer, M.D.

David S. Boyer, M.D., is a board-certified ophthalmologist specializing in the treatment of retinal and vitreous diseases. He is a Senior Partner at Retina-Vitreous Associates Medical Group. Dr. Boyer earned his medical degree at Chicago Medical School, completed his internship and residency at the University of Southern California/Los Angeles County Medical Center, and completed his fellowship in retinal surgery at the Wills Eye Hospital in Philadelphia. Dr. Boyer is a clinical professor of ophthalmology at the Keck School of Medicine of the University of Southern California and has an extensive research background. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. Dr. Boyer is a widely-published author and avid lecturer who lectures internationally on retinal research and innovative approaches to the treatment of retinal disease. He has authored and co-authored numerous works in peer-reviewed journals and has served as a reviewer for ophthalmology and diabetes medical publications, including Archives of Ophthalmology, American Journal of Ophthalmology, and Ophthalmology.

Jeffrey Heier, M.D.

Jeffrey Heier, M.D.

Dr. Heier is the Co-President, Medical Director, Director of the Vitreoretinal Service, and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the largest and most prestigious multi-specialty ophthalmology practices in the United States. He is also on the Executive Board of the Retina Society and the Executive Committee of the American Society of Retina Specialists. He is the Past President of the New England Ophthalmological Society, and is a member of the Macula Society. Dr. Heier has received several awards from the American Academy of Ophthalmology, including the Senior Achievement Award in 2010, the Secretariat Award in 2007, and the Honor Award in 2003. He is also the recipient of the Honor Award and Senior Honor Award from the American Society of Retina Specialists. Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He is a scientific advisor to several biotechnical or pharmaceutical companies, lectures nationally and internationally, and has authored numerous, peer-reviewed works. Dr. Heier received his medical degree from Boston University, did an internship and residency at Fitzsimons Army Medical Center, and a vitreoretinal fellowship at OCB/Tufts School of Medicine. Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.

Michael Allingham, M.D., Ph.D.

Michael Allingham, M.D., Ph.D.

Michael Allingham, M.D., Ph.D., is a retina trained clinician scientist with expertise in the diagnosis and treatment of macular diseases including diabetic retinopathy and edema, macular degeneration and retinal vein occlusion. Dr. Allingham attended Duke University where he earned a B.S. in Chemistry with Distinction. He pursued his M.D. / Ph.D. at the University of North Carolina. Upon completing his M.D. / Ph.D., he returned to Duke for his internship, residency in ophthalmology and fellowship in medical retina before accepting a faculty position in the Duke Eye Center Department of Ophthalmology where he is currently Assistant Professor.

Dr. Allingham's research is focused on the development of new therapies and diagnostics for macular diseases and he is particularly interested in mechanisms of vision loss due to macular edema as seen in diabetes and vein occlusion. He is active in basic laboratory research, clinical research focused on computerized analysis of retinal imaging as well as clinical trials for macular diseases. His research has received funding from the National Institutes of Health and he has published over 20 peer reviewed journal articles, reviews and book chapters.

David Brown, M.D., F.A.C.S

David Brown, M.D., F.A.C.S

David Brown, M.D. F.A.C.S. is the director of research at Retina Consultants of Texas, chair of the Medical Leadership Board of Retina Consultants of America (RCA), and a member of the RCA board of directors. Additionally, Dr. Brown is a Clinical Professor of Ophthalmology at Baylor College of Medicine, vice-chair for research for Houston Methodist Hospital, and is a member of NASA’s research and clinical advisory panel. Dr. Brown graduated from Baylor College of Medicine with highest honors and completed ophthalmology and retina training at the University of Iowa. He was a Thomas Heed Fellow, a Hermann Knapp Fellow, and was awarded the Ron Michels Fellowship award presented to the top retinal surgery fellow in the US in 1994.

Dr. Brown is a renowned leader in the retina and has published over 500 national meeting presentations, abstracts, and scientific papers, including many of the primary papers that established the use of anti-VEGF agents for AMD, retinal vein occlusion, and diabetic retinopathy (DR). He serves as a peer-reviewer for 8 ophthalmology journals and has authored 9 book chapters. Dr. Brown is an investigator in Ocuphire’s ZETA-1 Phase 2 clinical trial evaluating the safety and efficacy of oral APX3330 in patients with diabetic retinopathy.

David Lally, M.D.

David Lally, M.D.

David Lally, M.D. F.A.S.R.S. is a retina surgeon at Baystate Medical Center, an Assistant Professor of Ophthalmology at the University of Massachusetts Medical School-Baystate, and the director of the Retina Research Institute at New England Retina Consultants. Dr. Lally graduated from Vanderbilt University and received a medical degree from Jefferson Medical College. He completed ophthalmology residency at the Wills Eye Hospital in Philadelphia followed by a vitreoretinal fellowship at Tufts/New England Eye Center and Ophthalmic Consultants of Boston. He is an a is an active member of the American Society of Retina Specialists with the Fellow of the American Society of Retina Specialist (FASRS) award designation.

Dr. Lally’s work has been published in over 25 articles in peer-reviewed ophthalmic journals, and he has delivered over 25 presentations at national meetings. Dr. Lally is part of several clinical trial steering committees and an exceptional recruiter as principal investigator in numerous retina clinical trials. Dr. Lally is an investigator in Ocuphire’s ZETA-1 Phase 2 clinical trial.